- Home
- PRME vs VALN Comparison
PRME vs VALN Comparison
Compare PRME & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | VALN |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 536.9M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRME | VALN |
|---|---|---|
| Price | $3.43 | $5.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $7.56 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.6M | 92.8K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,632,000.00 | N/A |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $47.01 | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $1.11 | $5.15 |
| 52 Week High | $6.94 | $12.25 |
Technical Indicators
Market Signals| Indicator | PRME | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 28.79 |
| Support Level | $3.17 | $5.15 |
| Resistance Level | $3.97 | $6.42 |
| Average True Range (ATR) | 0.20 | 0.26 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 11.03 | 16.54 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.